Media headlines about Teva Pharmaceutical Industries (NYSE:TEVA) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.3105452341587 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.36 during trading on Friday, hitting $19.22. 13,264,900 shares of the stock were exchanged, compared to its average volume of 25,590,000. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market capitalization of $19,030.00, a P/E ratio of -3.27, a price-to-earnings-growth ratio of 1.39 and a beta of 0.54. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 1.77%. The ex-dividend date was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is -12.27%.
TEVA has been the topic of several recent research reports. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Evercore ISI set a $38.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, October 26th. Morgan Stanley set a $15.00 price objective on shares of Teva Pharmaceutical Industries and gave the company an “underweight” rating in a report on Thursday, October 5th. Finally, Mizuho reaffirmed a “hold” rating and set a $15.00 price objective on shares of Teva Pharmaceutical Industries in a report on Monday, October 30th. Seven investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $21.16.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Teva Pharmaceutical Industries (TEVA) Share Price” was first published by Equities Focus and is the sole property of of Equities Focus. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.equitiesfocus.com/2018/01/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-teva-pharmaceutical-industries-teva-share-price.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.